‘Global Radiopharmaceutical Market Worth Over $5 Billion In 2017’ Says Visiongain Report

16 August 2017
Pharma

Visiongain’s new report The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography indicates that the global Radiopharmaceutical market will see over $5bn in revenue in 2017.
The lead analyst of the report said:

“The market for radiopharmaceuticals is mainly driven by factors such as growth in R&D investments made in the biotechnology and pharmaceutical sector, technological advancements in nuclear medicine, the increasing burden of cancer and the ageing global population. The application of radiopharmaceuticals in diverse range of medical conditions will provide new growth opportunities to key players in the radiopharmaceutical market.

The competitive landscape of the global biosimulation market experiences intense competition to expand their share across globe. The Key players in the global biosimulation market include Siemens AG, Eckert & Ziegler, Lantheus Medical Imaging, Cardinal Health, Inc. and Bayer AG.
Technological advancements coupled with focus of key players focused on emerging nations to capitalize on their potential is expected to propel the growth of the global radiopharmaceutical market during the forecast period.”

The 234-page report contains 193 tables, charts and graphs that add visual analysis in order to explain developing trends within the Radiopharmaceutical market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Radiopharmaceutical submarkets. The market for radiopharmaceuticals is segmented based on application, radioisotope, source, end-user, and by geography. Based on application, the radiopharmaceutical market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology and Others. Based on radioisotope, the radiopharmaceutical market is segmented into Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111 and others. The radiopharmaceutical market by source market is segmented into cyclotrons and nuclear reactors. Based on the end-user the market is categorized into hospitals, diagnostic imaging centres, ambulatory surgical centres and cancer research institutes. The geographical breakdown includes analysis of North America, Latin America. Western Europe, Eastern Europe, Asia-Pacific, and MEA.

The 234-page report offers market forecasts and analysis for 6 regional and 21 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering
9 companies leading the Radiopharmaceutical field in detail.

The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography report will be of value to anyone who wants to better understand the radiopharmaceutical market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the radiopharmaceutical industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever